Comparative Pharmacology
Head-to-head clinical analysis: CLOLAR versus JYLAMVO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLOLAR versus JYLAMVO.
CLOLAR vs JYLAMVO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clolar (clofarabine) is a purine nucleoside antimetabolite that inhibits DNA synthesis and RNA transcription. It is phosphorylated intracellularly to its active triphosphate form, which competes with adenosine triphosphate for incorporation into DNA, leading to chain termination and inhibition of DNA polymerase and ribonucleotide reductase, resulting in apoptosis.
JYLAMVO (methotrexate) is a folate analog that inhibits dihydrofolate reductase (DHFR), thereby disrupting DNA synthesis and repair. It also inhibits purine and thymidylate synthesis, leading to immunosuppressive and antineoplastic effects.
5 mg/m2 intravenously over 2 hours daily for 5 consecutive days. Repeat every 28 days.
Oral: 30 mg twice daily for adults with relapsed or refractory acute myeloid leukemia (AML) as a monotherapy.
None Documented
None Documented
Terminal elimination half-life approximately 5.2 hours in patients with normal renal function; prolonged in renal impairment (up to 9.8 hours with CrCl <60 mL/min) and in elderly; clinical context: supports once-daily dosing adjustment for renal function.
Terminal elimination half-life is 12-16 hours in adults with normal renal function; prolonged to 24-48 hours in severe renal impairment (CrCl <30 mL/min).
Renal: 50-60% as unchanged drug; biliary/fecal: minimal (<5%)
Primarily renal elimination as unchanged drug (approximately 70-80%) with minor biliary/fecal excretion (20-30%).
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent